Edition:
United Kingdom

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

9.28USD
20 Apr 2018
Change (% chg)

$-0.04 (-0.43%)
Prev Close
$9.32
Open
$9.29
Day's High
$9.54
Day's Low
$9.16
Volume
152,175
Avg. Vol
145,991
52-wk High
$20.25
52-wk Low
$9.04

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $894.46
Shares Outstanding(Mil.): 47.15
Dividend: --
Yield (%): --

Financials

  AKBA.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -3.62 -- --
ROI: -85.01 1.58 14.38
ROE: -147.39 2.41 16.07

BRIEF-Akebia Therapeutics Announces Proposed Public Offering Of Common Stock

* AKEBIA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

22 Mar 2018

BRIEF-Akebia Therapeutics Inc Files For Potential Mixed Shelf Offering Amount Not Disclosed - SEC Filing

* AKEBIA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; AMOUNT NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2tG5aJJ) Further company coverage: (Reuters.Brief@thomsonreuters.com)

12 Mar 2018

BRIEF-Akebia Therapeutics Announces Q4 Earnings Per Share $0.25

* AKEBIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

12 Mar 2018

BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program

* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM

12 Feb 2018

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results

08 Nov 2017

BRIEF-Invirsa secures seed financing to develop new approach

* Invirsa secures seed financing to develop new approach to treating common infectious diseases that affect millions annually Source text for Eikon: Further company coverage:

07 Nov 2017

Competitors

  Price Chg
Amgen, Inc. (AMGN.OQ) $171.56 -1.37
Johnson & Johnson (JNJ.N) $126.66 -0.89
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20
FibroGen Inc (FGEN.OQ) $46.40 -0.20
AstraZeneca plc (AZN.L) 4,976.00 +20.50
Astellas Pharma Inc (4503.T) ¥1,582 -10.00
GlaxoSmithKline plc (GSK.L) 1,430.00 +22.60
Bayer AG (BAYGn.DE) €99.00 -0.60
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates